PT-141 (Bremelanotide) and Rosuvastatin Interaction

Why This Combination Comes Up

Patients prescribed rosuvastatin for dyslipidemia may also receive bremelanotide (marketed as Vyleesi) for hypoactive sexual desire disorder (HSDD) or, off-label, for erectile dysfunction. The overlap is common: cardiovascular risk factors and sexual dysfunction frequently coexist, especially in adults over 40. A 2013 analysis in the Journal of Sexual Medicine estimated that 42% of women with HSDD had at least one cardiovascular comorbidity requiring pharmacotherapy [1].

Clinicians evaluating this pairing need to answer two questions. First, does either drug alter the other's plasma concentration? Second, do their pharmacodynamic effects compound risk?

The Clinical Scenario

A premenopausal woman on rosuvastatin 10 mg daily for familial hypercholesterolemia receives a bremelanotide prescription for HSDD. Her prescriber checks for interactions. The same question arises for men using PT-141 off-label alongside a statin. Both scenarios require the same pharmacologic analysis.

Why Standard Databases Fall Short

Most commercial drug-interaction databases (Lexicomp, Micromedex) classify bremelanotide interactions as limited data. That label reflects the drug's 2019 approval and relatively small post-marketing exposure, not a known hazard. The absence of a flagged interaction is not the same as proof of safety, so a mechanism-level review matters.

Pharmacokinetic Analysis: Metabolism and Transport

Bremelanotide and rosuvastatin use almost entirely separate metabolic and transport systems. That separation is the primary reason no clinically meaningful pharmacokinetic interaction is expected.

How Bremelanotide Is Cleared

Bremelanotide is a cyclic heptapeptide. It undergoes hydrolysis into amino acid fragments rather than oxidative metabolism through cytochrome P450 enzymes [2]. The FDA-approved label for Vyleesi states that bremelanotide is "not a substrate, inhibitor, or inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations" [2]. It is not a significant substrate or inhibitor of P-glycoprotein (P-gp), OATP1B1, or OATP1B3.

Peak plasma concentration after a 1.75 mg subcutaneous injection occurs at roughly 1 hour, and the elimination half-life is approximately 2.7 hours [2]. The drug is essentially cleared within 12 to 15 hours.

How Rosuvastatin Is Cleared

Rosuvastatin has a distinct metabolic profile among statins. It is minimally metabolized by CYP2C9, with roughly 10% of the dose undergoing oxidative biotransformation [3]. The dominant clearance mechanism involves hepatic uptake via OATP1B1 and OATP1B3 transporters, followed by biliary excretion. Rosuvastatin is also a substrate of BCRP (breast cancer resistance protein) [3].

Drugs that inhibit OATP1B1/1B3 (cyclosporine, certain protease inhibitors, gemfibrozil) can raise rosuvastatin AUC by 2- to 7-fold and increase myopathy risk [3]. This is the pathway that matters for rosuvastatin drug interactions.

The Interaction Gap

Because bremelanotide does not inhibit OATP1B1, OATP1B3, BCRP, or CYP2C9, it should not alter rosuvastatin plasma levels. Conversely, rosuvastatin does not affect peptide hydrolysis pathways, so it should not change bremelanotide exposure. No published pharmacokinetic study has tested the combination directly, but the mechanistic data from both FDA labels makes a significant interaction unlikely [2][3].

Pharmacodynamic Considerations: Blood Pressure and Vascular Effects

The pharmacodynamic interaction profile deserves more attention than the pharmacokinetic one. Bremelanotide affects blood pressure through melanocortin receptor activation, and any hemodynamic shift is relevant when a patient is also managing cardiovascular risk.

Bremelanotide's Hemodynamic Signature

In the RECONNECT phase 3 trials (combined N=1,247), bremelanotide 1.75 mg subcutaneous produced a mean systolic blood pressure increase of approximately 6 mmHg and a mean heart rate decrease of approximately 5 bpm, peaking 2 to 3 hours post-dose and resolving within 12 hours [4]. The FDA label carries a specific warning: bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [2].

The blood pressure rise was generally transient and self-limited in trial participants. But individual responses varied. Some patients experienced increases exceeding 10 mmHg systolic.

Rosuvastatin's Vascular Profile

Rosuvastatin itself has a mild blood-pressure-lowering effect observed in some studies. A 2014 meta-analysis of 40 RCTs found that statins reduced systolic BP by a mean of 1.9 mmHg in hypertensive patients [5]. This effect is modest and would not meaningfully offset bremelanotide's pressor activity.

Net Hemodynamic Risk

The two drugs do not produce a synergistic hemodynamic hazard. Rosuvastatin does not amplify bremelanotide's blood pressure increase. The concern is unidirectional: bremelanotide's pressor effect in a patient whose cardiovascular risk profile warranted statin therapy. If blood pressure is already well-controlled, the transient 6 mmHg rise is unlikely to cause harm. If blood pressure is borderline or poorly controlled, bremelanotide should not be initiated regardless of statin use.

Myopathy and Muscle-Related Risks

Statin-associated muscle symptoms (SAMS) affect an estimated 7 to 29% of statin users depending on the definition used, though confirmed rhabdomyolysis remains rare at roughly 1 to 3 per 100,000 patient-years [6]. Any co-administered drug that raises statin plasma levels increases this risk. Bremelanotide does not.

Why Bremelanotide Does Not Raise Myopathy Risk

The drugs that increase rosuvastatin-associated myopathy risk do so by inhibiting hepatic uptake (OATP1B1/1B3) or renal elimination. Cyclosporine increases rosuvastatin AUC 7.1-fold. Lopinavir/ritonavir increases it 2.1-fold [3]. Bremelanotide has no effect on these pathways.

When to Check CK Levels

Standard statin monitoring applies. The 2018 AHA/ACC cholesterol guidelines recommend measuring creatine kinase (CK) only when a patient reports new muscle symptoms, not as routine surveillance [7]. Adding bremelanotide does not change this recommendation. If a patient on both drugs reports new-onset myalgia, evaluate CK and consider the statin first. Bremelanotide-associated musculoskeletal complaints were rare in RECONNECT data (reported in <2% of participants, similar to placebo) [4].

Hepatic Safety

Both drugs have hepatic considerations, though neither carries a strong hepatotoxicity signal at standard doses.

Rosuvastatin and Liver Enzymes

Rosuvastatin can cause transaminase elevations. The JUPITER trial (N=17,802) found ALT elevations exceeding 3x the upper limit of normal in 0.3% of rosuvastatin-treated patients versus 0.2% on placebo [8]. Current guidelines no longer recommend routine periodic LFT monitoring for statins, though baseline measurement before initiation is standard [7].

Bremelanotide and the Liver

Bremelanotide is not associated with significant hepatotoxicity. It bypasses hepatic CYP metabolism entirely. No liver enzyme monitoring is specified in the Vyleesi label [2]. In RECONNECT trials, hepatic adverse events did not differ between bremelanotide and placebo groups [4].

Combined Hepatic Monitoring

No additive hepatic risk is expected. Baseline hepatic function testing before statin initiation covers both drugs. If transaminases rise, the statin is the more likely cause.

Dosing and Administration Guidance

No dose adjustment of either drug is required based on the co-administration.

Bremelanotide Dosing

The approved dose is 1.75 mg subcutaneous, self-administered in the abdomen or thigh at least 45 minutes before anticipated sexual activity [2]. Maximum frequency: once per 24 hours, no more than 8 doses per month. These limits exist because of the blood pressure effect and nausea profile, not because of drug interactions.

Rosuvastatin Dosing

Standard dosing ranges from 5 to 40 mg daily, with 40 mg reserved for patients who have not reached LDL-C goals on 20 mg [3]. The dose should be adjusted for renal impairment (GFR <30 mL/min: start at 5 mg, max 10 mg) and for patients of East Asian descent, who may have higher rosuvastatin exposure due to OATP1B1 polymorphisms [3].

Timing Considerations

Bremelanotide reaches peak concentration at 1 hour and clears within 12 to 15 hours. Rosuvastatin is typically taken in the evening, though unlike short-acting statins, it can be taken at any time of day due to its 19-hour half-life [3]. There is no pharmacokinetic reason to separate their dosing times, but taking rosuvastatin at its usual scheduled time and bremelanotide on an as-needed basis avoids unnecessary complexity.

Patient Counseling Points

Clinicians should cover four topics when a patient uses both drugs.

Blood Pressure Self-Monitoring

Patients should check blood pressure before bremelanotide injection, especially during the first few uses. If systolic BP exceeds 140 mmHg or diastolic exceeds 90 mmHg at baseline, the dose should be withheld and the prescriber contacted. A home blood pressure monitor (validated oscillometric device) is sufficient.

Nausea Management

Nausea is the most common bremelanotide side effect, affecting 40% of patients in the RECONNECT trials versus 1% on placebo [4]. Nausea peaked with the first dose and diminished with subsequent use. Patients should know this is expected and not related to rosuvastatin.

Muscle Symptom Awareness

Patients on any statin should report new or unexplained muscle pain, tenderness, or weakness. Bremelanotide does not increase this risk, but patients on multiple medications sometimes attribute new symptoms to the wrong drug. Clear counseling prevents unnecessary discontinuation of either therapy.

Alcohol and Timing

Both drug labels note caution with alcohol. Rosuvastatin's label mentions that concurrent alcohol use may increase the risk of hepatic effects [3]. Bremelanotide's label notes that alcohol was allowed in clinical trials but advises awareness of additive sedation or hypotension [2]. Patients should avoid excessive alcohol around bremelanotide dosing.

Special Populations

Renal Impairment

Rosuvastatin requires dose reduction in severe renal impairment. Bremelanotide AUC increased by approximately 70% in subjects with severe renal impairment (eGFR <30), and the Vyleesi label recommends avoiding use in this population [2]. If both drugs are prescribed to a patient with moderate renal impairment, rosuvastatin dose capping and careful blood pressure monitoring apply.

Hepatic Impairment

Rosuvastatin is contraindicated in active liver disease or unexplained persistent transaminase elevations [3]. Bremelanotide has not been studied in hepatic impairment, but its non-hepatic metabolism makes accumulation unlikely [2]. Statin contraindication status should drive the decision.

Pregnancy

Bremelanotide is approved only for premenopausal women, and pregnancy testing is recommended before each dose per the FDA label [2]. Rosuvastatin is contraindicated in pregnancy [3]. Women of reproductive age on both drugs need reliable contraception.

Summary of the Interaction Profile

The bremelanotide-rosuvastatin combination does not produce a pharmacokinetic drug-drug interaction based on available mechanistic data. No CYP, OATP, P-gp, or BCRP overlap exists at clinical doses. The pharmacodynamic consideration is bremelanotide's transient pressor effect in a patient whose cardiovascular risk warranted statin therapy. Pre-dose blood pressure checks and standard statin monitoring are sufficient. No dose adjustment is needed for either drug.

Patients with uncontrolled hypertension should not receive bremelanotide regardless of statin use. For all others, the combination can be used with routine clinical oversight. The 2018 AHA/ACC guideline recommendation for statin monitoring [7] and the Vyleesi prescribing information [2] together cover the necessary surveillance.